Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir

Int J Antimicrob Agents. 2004 Sep;24(3):284-5. doi: 10.1016/j.ijantimicag.2004.04.005.

Abstract

The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen.

Publication types

  • Case Reports

MeSH terms

  • Adenine / adverse effects*
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Hydronephrosis / chemically induced*
  • Kidney Calculi / chemically induced*
  • Male
  • Organophosphonates / adverse effects*
  • Organophosphonates / therapeutic use
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Tenofovir
  • Adenine